sum11 pharma.pdf

Upload: mostofa-rubal

Post on 04-Jun-2018

223 views

Category:

Documents


0 download

TRANSCRIPT

  • 8/14/2019 sum11 pharma.pdf

    1/29

    &

    G..

    C E

    65

    NSF ERCFOR STRUCTURED ORGANICPARTICULATE SYSTEMS

  • 8/14/2019 sum11 pharma.pdf

    2/29

    I

    E

    /

    IE

    EC

  • 8/14/2019 sum11 pharma.pdf

    3/29

    3

    39.80%

    30.60%, , 12.70%

    11.20%

    5.70%

    $800+ Billion/yGlobal Business!

    Source: IMS Health Market Prognosis, March 2010

  • 8/14/2019 sum11 pharma.pdf

    4/29

    D D C

    Cost Component Distribution

    Discover 20- 25%

    C D $0.8 B $2 B

    A &D $60 B

    Safety & Toxicology 1520%

    Product DevelopmentAPI process design

    Product formulation & process designClinical supply

    3035%

    Clinical Trials ( Phase I-III) 35-40%

    & , , , 151 (200)

  • 8/14/2019 sum11 pharma.pdf

    5/29

    Disposition of salesrevenue of 8 largestresearch-basedpharmaceuticalmanufacturers

    ManufacturingCOGS27%

    After TaxAccounting Profit

    18%

    Taxes

    U.S. pharmaceuticalexpenditures in 2009~ $320 B

    (IMS Health and PMPRBAnnual Report, 2010)

    COGS (U.S) = ~ $90 B .. , , 136, / 2001

    7%

    R&D13% Sales & General

    Administration

    35%

  • 8/14/2019 sum11 pharma.pdf

    6/29

    D &

    D A

    L

    ()

    NHHO

    O

    CH3

    6

    D , , ,

    , ,

    /

    G

  • 8/14/2019 sum11 pharma.pdf

    7/29

    ExcipientsAPI

    Dosage Form

    /

  • 8/14/2019 sum11 pharma.pdf

    8/29

    C A : &

    D &

    FDA & ()

    F &

    C ,

    : DD D

    C D C A &

  • 8/14/2019 sum11 pharma.pdf

    9/29

    E A

    & DAI

    & D

    I B C

    E D D

    ( CACE 2008; CACE 2008)

    C C (496)

    C C (L , CACE 2009,2010)

  • 8/14/2019 sum11 pharma.pdf

    10/29

    D

    Quantitative definitionFor selected set of equipment design

    parameters

    Probability distributions of feed

    The established range of process parameters that has

    been demonstrated to provide assurance of quality.

    I A

    Probability distributions ofinternal process variables

    Required probability of meetingproduct critical quality attributes

    Design space:Multidimensional region defined byranges of operating variablescontaining all variable adjustmentsnecessary to achieve desiredprobability of meeting product CQA

    CA

    D

  • 8/14/2019 sum11 pharma.pdf

    11/29

    D C :

    & E.., F ,

    A , ,

    )C ( ,

    )

    CA

    C I:

    &

  • 8/14/2019 sum11 pharma.pdf

    12/29

    %

    BloodL

    evel

    H

    D & D

    I

    D

    D

    D

    C

    D

    D

    C

    C

    D

    AI (, )

    D

    E

  • 8/14/2019 sum11 pharma.pdf

    13/29

    Manuf.

    Design

    Space

    Degradant

    Unstable

    form

    Post-

    Manufacturing

    Degradation

    Drug

    Expiry

    2.0

    2.5

    60 min

    milled

    30

    40

    50

    5% H 30% H

    I D

    %

    13

    0 5 10 15 20 25 30

    0.0

    0.5

    1.0

    1.5

    %l

    actam

    time(days)

    milled

    15 min

    milled

    API as

    received 0

    10

    20

    0 100 200 300 400 500 600

    50% H

    D

    D

    &

    ()

    L

  • 8/14/2019 sum11 pharma.pdf

    14/29

    D C : G

    Excipients

    Binder

    Lubricants

    O OH

    NH2 NH

    O

    gabapentin lactam

    AI

    H (70%): HC,

    CC, C,

    2011

    /

    WetGranulation

    Fluid BedDrying

    Blending Tabletting

    API

    G: D A D

    D

    +

    (

    )

  • 8/14/2019 sum11 pharma.pdf

    15/29

    I

    E

    / IE

  • 8/14/2019 sum11 pharma.pdf

    16/29

    NSF ERC for Structured Organic Particulate SystemsNSF ERC for Structured Organic Particulate Systems

    30 Faculty

    16

    50+ PhDstudents &postdocsIndustrial

    partners26

    Launched

    July 2006

  • 8/14/2019 sum11 pharma.pdf

    17/29

    CC--SOPS ObjectivesSOPS Objectives

    Develop scientific foundation foroptimal design of structured organiccomposite products for

    pharmaceutical, nutraceutical &agrochemical industries

    Develop science and engineeringmethods for desi nin scalin

    NAE 2008

    17

    optimizing and controlling relevantmanufacturing processes.

    Demonstrate developedfundamentals on novel test beds.

    Establish effective educational andtechnology transfer vehicles. Engineer

    better medicines !

    Personalized medicine

  • 8/14/2019 sum11 pharma.pdf

    18/29

    Thrust D: Integrated Systems Science

    Model predictive design and operation ofintegrated particulate processes

    Thrust Leader: Venkat Venkatasubramanian (PU)

    Thrust B projec Thrust B proThrust D projects

    18

    D-1 Sensing MethodologiesD-2 Hardware and Software Integration

    D-3 Ontological Informatics Infrastructure

    D-4 Real-time Process Management

    D-5 Integrated Design and Optimization

    Demonstration on Test Beds

  • 8/14/2019 sum11 pharma.pdf

    19/29

    Data, Information, ModelsData, Information, Models

    1. Feeder Screw Speed (rpm) Vibration if resent

    7. Pneumatic Transfer

    6. Transfer Receptacle Monitor mass over time

    8. Tablet Press Fill weight

    Pressure RPM Feed Frame RPM Feed Frame Blade

    Speed Punch Distance

    12

    3

    4

    4. Roll Compactor Roll Speed Hydraulic Pressure Feed rate Roll Gap

    Ribbon Content

    Uniformity Ribbon Density (NIR)

    5. Mill Milling Speed Particle Size

    Continuous Granulation Line

    19

    Powder Flow

    Powder Level in Hopper

    2. Continuous Blender Tilt Speed (rpm) Load (mass/level) Inlet Powder Flow

    Content Uniformity (NIR) Density (X-ray/Microwave

    /NIR)

    Outlet Powder Flow

    9. Tablets Weight

    Tensile strength

    Density

    n e ow er ow

    Content Uniformity Density (NIR)

    Tablet Weight

    Tablet Density

    Feed Frame Outlet

    Flow

    Powder Density

    Powder Segregation85

    6

    7

    9

    3. Feed Hopper / Screw Screw Speed (rpm) Vacuum Pressure

    Powder Level in Hopper Density at RC Entrance

  • 8/14/2019 sum11 pharma.pdf

    20/29

    Information Ontology ArchitectureInformation Ontology Architecture

    GUI

    Decisions Knowledge Models

    20

    Information

    Computationaltools

    Unstructured information

    Venkatasubramanian AICHE J 2009

  • 8/14/2019 sum11 pharma.pdf

    21/29

    Real Time Process Management

    21

  • 8/14/2019 sum11 pharma.pdf

    22/29

    Process FaultsProcess Faults & Disturbances& Disturbances

    2. Continuous Blender (DEM,Compartment)

    No Content Uniformity

    5. Mill (PBM) No Flow (screens clog/foul) Undesired Particle Size (over-milling)

    RPM

    6. Transfer Receptacle

    8. Tablet Press (FEM) Flow Variability Incorrect Density Powder Segregation

    7. Pneumatic Transfer

    All Unit Operations Max/Min Limits of

    Manipulated VariablesReached2

    3

    4

    7

    1Unit Operation

    DEM

    Neural Nets

    22

    . Insufficient Shear Force Generating Electrostatics

    No Flow RPM/Motor Malfunction Tilt Angle Cohesiveness

    4. Roll Compactor (FEM)

    Undesired Density Pressure RPM/Motor Malfunction Feed Screw / Roll Speed

    Ratio No Content Uniformity No Flow No Compaction

    PSD Variation

    Mass Accumulation Bridging Whiskering Dissolution Weight Variation Picking High Friability Sticking Capping Lamination Weak (Tensile Strength)

    85

    6

    9

    Statistical

    DAE

    Solvers

  • 8/14/2019 sum11 pharma.pdf

    23/29

    Roller Compaction Model Management in POPE

    Johansons rolling model with timevariation of roll gap included

    10/11/2005

    23

    ENGINEERING RESEARCH CENTER FOR

    STRUCTURED ORGANIC PARTICULATE SYSTEMS

    RUTGERS UNIVERSITYPURDUE UNIVERSITY

    NEW JERSEY INSTITUTE OF TECHNOLOGYUNIVERSITY OF PUERTO RICO AT MAYAGEZ

    Model and OperationOntology JAVA Engine and

    GUI

  • 8/14/2019 sum11 pharma.pdf

    24/29

  • 8/14/2019 sum11 pharma.pdf

    25/29

    EEM: Alexanderwerk Roller Compactor

    Roll GapFeed Screw Speed

    Hydraulic Pressure

    RollSpeed

    25

    Feedback Control

    Event: No powder entering roll region

    Causes: No powder in hopperBlockage in hopper

    Jam in nip region

    Event: No powder entering roll region

    Causes: No powder in hopperBlockage in hopper

    Jam in nip region

  • 8/14/2019 sum11 pharma.pdf

    26/29

    Exceptional Events Management

    HydraulicPressure

    Delta-V FaultDetection

    Mitigation strategy isautomated wheneverpossible; otherwise, a

    strategy is suggestedto the operator

    26

    RollGap

    Feed ScrewSpeed

    FeedbackControl

    RollSpeed

    FaultDiagnosis

    FaultMitigation

  • 8/14/2019 sum11 pharma.pdf

    27/29

    Feeders

    Blender

    Multi-pointNIR

    10/11/2005

    27

    ENGINEERING RESEARCH CENTER FOR

    STRUCTURED ORGANIC PARTICULATE SYSTEMS

    RUTGERS UNIVERSITYPURDUE UNIVERSITY

    NEW JERSEY INSTITUTE OF TECHNOLOGYUNIVERSITY OF PUERTO RICO AT MAYAGEZ

    TabletPress

    Delta VControl System

    Optical

    Tablet thicknessMeasurement

  • 8/14/2019 sum11 pharma.pdf

    28/29

    AICE 2010

    383,G , F C I I

    444, H , E E C

    : F, B, & C

    456, L , A CI C K D: HB

    456, J , : I

    596, G , C : I

    697,L , I C I FBAED

    D F 444,K , D C

    ()

  • 8/14/2019 sum11 pharma.pdf

    29/29

    SummarySummary

    Changes in business environment have openedexiting opportunities for development and

    application of PSE methodology. Product /process design challenges: linking input

    material properties & manufacturing conditions to

    29

    o pro uc s e e erapeu c per ormance

    Key process operations challenges: predicting &optimizing performance of particulate and/orheterogeneous multicomponent systems

    Risk management is critical: opportunity forexploitation of quantitative Bayesian basedestimation and analysis methods